On April 22, 2022 the WHO publish update for their Therapeutics and COVID-19: living guideline document where they now conditionally recommend the antiviral remdesivir, with ONLY ONE mode of action, for early treatment , “in patients with non-severe COVID-19″ to prevent hospitalisation – what the COVID-19 vaccines were meant to do. [1]
Cheap hydroxychloroqine, with multiple modes of action, is not recommended for “any severity” of COVID-19!